MUDr. Eva Dokoupilová, Ph.D., MBA

VETCHÝ, D., PAVLOKOVÁ, S., VETCHÁ, M., DOKOUPILOVÁ, E. Adalimumab a infliximab – porovnání originálních a biosimilárních léků pomocí vícerozměrné analýzy dat. Farmakoterapie. 2018;14(suppl. 7):8–12.

DOKOUPILOVÁ, E., AELION, J., TAKEUCHI, T., MALAVOLTA, N., SFIKAKIS, P., WANG, Y., RICHARDS, H. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis. Scandinavian Journal of Rheumatology. 2018; 47(4): 276–281. https://doi.org/10.1080/03009742.2017.1390605
Q3, IF₂₀₂₃2, Number of Citation: 33

SMOLEN, J.S., CHOE, J.Y., PRODANOVIC, N., NIEBRZYDOWSKI, J., STAYKOV, I., DOKOUPILOVA, E., BARANAUSKAITE, A., YATSYSHYN, R., MEKIC, M., PORAWSKA, W., CIFERSKA, H., JEDRYCHOWICZ-ROSIAK, K., ZIELINSKA, A., LEE, Y., RHO, Y.H. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018 Feb;77(2):234-240. doi: 10.1136/annrheumdis-2017-211741.
Q1, IF₂₀₂₃3, Number of Citation: 95

NASH, P., MEASE, P.J., MCINNES, I.B. et al.Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018; 20: 47. https://doi.org/10.1186/s13075-018-1551-x
Q1, IF₂₀₂₃4, Number of Citation: 128

WEINBLATT, M.E., BARANAUSKAITE, A., DOKOUPILOVA, E., ZIELINSKA, A., JAWORSKI, J., RACEWICZ, A., PILECKYTE, M., JEDRYCHOWICZ-ROSIAK, K., BAEK, I. AND GHIL, J. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2018; 70: 832-840. https://doi.org/10.1002/art.40444
Q1, IF₂₀₂₃4, Number of Citation: 97

GENOVESE, M. C., GLOVER, J., GREENWALD, M., PORAWSKA, W., CHALOUHI EL KHOURI, E., DOKOUPILOVA, E., VARGAS, J. I., STANISLAVCHUK, M., KELLNER, H., BARANOVA, E., MATSUNAGA, N. AND ALTEN, R. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Research & Therapy. 2019, 21:281.
Q1, IF₂₀₂₃4, Number of Citation: 38

PAVELKA, K., BERNETTI, A., GIORDAN, N., DOKOUPILOVÁ, E., SANTILLI, V. Dose-response of hyaluronate-based viscoelastic hydrogels for the treatment of knee osteoarthrosis: a prospective, randomized, comparative clinical trial. Minerva Ortopedica e Traumatologica. 2020 June;71(2):45-55.

PAVELKA, K., KIVITZ, A. J., DOKOUPILOVA, , BLANCO, R., MARADIAGA, M., TAHIR, H., WANG, Y., PORTER, B. O., STEFANSKA, A., RICHARDS, H. B.  AND ROHRER, S. on behalf of the MEASURE 3 study group. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatology Vol. 2, No. 2, February 2020, pp 119 – 127.

PELLETIER, J. P., J. P. RAYNAULD, M. DORAIS, L. BESSETTE,  DOKOUPILOVÁ, E., F. MORIN, K. PAVELKA, P. PAIEMENT a J. MARTEL-PELLETIER. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. RHEUMATOLOGY. OXFORD: OXFORD UNIV PRESS, 2020, roč. 59, č. 12, s. 3858-3868. ISSN 1462-0324. Dostupné z: https://dx.doi.org/10.1093/rheumatology/keaa072.
Q1, IF₂₀₂₃7, Number of Citation: 22

WILAND, P., S. JEKA, DOKOUPILOVÁ, E., J. BRANDT-JURGENS, J. M. M. LIMON, M. C. MOREIRA, R. V. CABELLO, J. JAUCH-LEMBACH, A. THAKUR, H. HALIDUOLA, I. BRUECKMANN a N. B. GAYLIS. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. BIODRUGS. NORTHCOTE: ADIS INT LTD, 2020, roč. 34, č. 6, s. 809-823. ISSN 1173-8804. Dostupné z: https://dx.doi.org/10.1007/s40259-020-00447-6.
Q1, IF₂₀₂₃4, Number of Citation: 29

ORBAI, A.M., J. GRATACOS, A. TURKIEWICZ, S. HALL, DOKOUPILOVÁ, E., B. COMBE, P. NASH, G. GALLO, C.C. BERTRAM, A.M. GELLETT, A. T. SPRABERY, J. BIRT, L. MACPHERSON, V.J. GENEUS a A. CONSTANTIN. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). RHEUMATOLOGY AND THERAPY. NEW YORK: SPRINGER, 2020, roč. 8, č. 1, s. 199-217. ISSN 2198-6576. Dostupné z: https://dx.doi.org/10.1007/s40744-020-00261-0.
Q2, IF₂₀₂₃9, Number of Citation: 9

MEASE, P.J., A. LERTRATANAKUL, K.A. PAPP, F.E. VAN DEN BOSCH, S. TSUJI, DOKOUPILOVÁ, E., M.W. KEISERMAN, X.W. BU, L. CHEN, R.M. MCCASKILL, P. ZUEGER, E.L. MCDEARMON-BLONDELL, A.L. PANGAN a W. TILLETT. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. RHEUMATOLOGY AND THERAPY. NEW YORK: SPRINGER, 2021, roč. 8, č. 2, s. 903-919. ISSN 2198-6576. Dostupné z: https://dx.doi.org/10.1007/s40744-021-00305-z.
Q1, IF₂₀₂₃3, Number of Citation: 90

FLEISCHMANN, R. M., BOCK, A. E., ZHANG, W., GODFREY, C. M., VRANIC, I., CRONENBERGER, C., DOKOUPILOVÁ, E. Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. RHEUMATOLOGY AND THERAPY. NEW YORK: SPRINGER, 2022, roč. 9, č. 3, s. 839-850. ISSN 2198-6576. Dostupné z: https://dx.doi.org/10.1007/s40744-022-00439-8.
Q2, IF₂₀₂₃9, Number of Citation: 3

BEHRENS, F., SEWERIN, P., Eugenio DE, M., PATEL, Y., BATALOV, A., DOKOUPILOVÁ, E., KLEINMOND, C., POURNARA, E., SHEKHAWAT, A., JENTZSCH, C., WIEDON, A., BARALIAKOS, X. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial. RHEUMATOLOGY. OXFORD: OXFORD UNIV PRESS, 2022, Neuveden., November, s. 1-11. ISSN 1462-0324. Dostupné z: https://dx.doi.org/10.1093/rheumatology/keab784.
Q1, IF₂₀₂₃7, Number of Citation: 9

JEKA, S., DOKOUPILOVÁ, E., KIVITZ, A., ZUCHOWSKI, P., VOGG, B., KRIVTSOVA, N., SEKHAR, S., BANERJEE, S., SCHWEBIG, A., POETZL, J., BODY, J.-J., EASTELL, R. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. Journal of bone and mineral research. Hoboken: Wiley, 2024, roč. 39, č. 3, s. 202-210. ISSN 0884-0431. Dostupné z: https://dx.doi.org/10.1093/jbmr/zjae016.
Q1, IF₂₀₂₃1, Number of Citation: 0

DOKOUPILOVÁ, E.,  VETCHÝ, D., PAVLOKOVÁ, S., HANUŠTIAKOVÁ, M.. Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. NETHERLANDS: SPRINGER, 2024, Neuveden, č. 7, s. 1-10. ISSN 2210-7703. Dostupné z: https://dx.doi.org/10.1016/j.ijpx.2024.100229.
Q1, IF₂₀₂₃2, Number of Citation: 0

LANGDAHL, B., CHUNG, Y.-S., PLEBANSKI, R., CZERWINSKI, E., DOKOUPILOVA, E., SUPRONIK, J., ROSA, J., MYDLAK, A., ROWIŃSKA-OSUCH, A., BAEK, K.-H., URBONIENE, A., MORDAKA, R., AHN, S., RHO, Y. H., BAN, J., EASTELL, R. Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12, The Journal of Clinical Endocrinology & Metabolism, 2024; dgae611, https://doi.org/10.1210/clinem/dgae611
Q1, IF₂₀₂₃ 5, Number of Citation: 0

ORBAI, A. M., GRATACOS-MASMITJA, J., DOKOUPILOVA, , COMBE, B., CONSTANTIN, A., GELLETT, A. M., SPRABERY, A. T., BIRT, J., GENEUS, V., NASH, P. Sustained improvements in physical function, quality of life, and work productivity with ixekizumab in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors: 3-year results from SPIRIT-P2 trial. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1705. (EULAR 2020)

BRAUN, J., BLANCO, R., DOKOUPILOVA, E., GENSLER, L. S., KIVITZ, A., HALL, S., KAMEDA, H., PODDUBNYY, D., VAN DE SANDE, M., VAN DER HEIJDE, D., WIKSTEN, A., PORTER, B., RICHARDS, H., HAEMMERLE, S. , DEODHAR, A. Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase 3 prevent study. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 69. (EULAR 2020)

GENOVESE, M. C., LERTRATANAKUL, A. , ANDERSON, J.,  PAPP, K.,  TILLETT, W., VAN DEN BOSCH, F., TSUJI, S., DOKOUPILOVA, , KEISERMAN, M., WANG, X., ZHONG, S., ZUEGER, P., PANGAN, A., MEASE, P. J. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 139. (EULAR 2020)

GRATACOS-MASMITJA, J., TURKIEWICZ, A., DOKOUPILOVA, , GELLETT, A. M., SPRABERY, A. T.,  GENEUS, V. J., CONSTANTIN,  A. Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to tnf inhibitors: three year results from a phase 3 study (SPIRIT-P2). Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1154. (EULAR 2020)

DEODHAR, A., BLANCO, R., DOKOUPILOVA, ,  VAN DE SANDE, M., HALL, S., WIKSTEN, A., PORTER, B.O., RICHARDS, H. B., HAEMMERLE, S., BRAUN, J. Secukinumab 150 mg Significantly Improved Signs and Symptoms of Nonradiographic Axial Spondyloarthritis: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Study. Poster presented at the Phoenix Rheumatology Association (PRA) Rheumatology Update: Highlights From ACR 2019; January 18, 2020

BEHRENS, F. SEWERIN, P., DE MIGUEL, E., PATEL, Y., BATALOV, A., DOKOUPILOVA, E., KLEINMOND, C., POURNARA, E., SHEKHAWAT, A., JENTZSCH, C., WIEDON, A., BARALIAKOS, X. Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spodyloarthritis: Baseline Results from a Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). (ACR 2019).

DEODHAR, A., BLANCO, R., DOKOUPILOVA, E., VAN DE SANDE, M., HALL, S., WIKSTEN, A. S., PORTER, B. O., RICHARDS, H. B., HAEMMERLE, S., BRAUN, J. Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondylosrthritis: Results from a Phase 3 Double blind, Randomized, Placebo-controlled Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl. 10). (ACR 2019).

PAVELKA, K., KIVITZ, A.J., DOKOUPILOVA, E., BLANCO, R., MARADIAGA, M., TAHIR, H., SLADE, A., WANG, Y., ROHRER, S., PORTER, B. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

DEODHAR, A., BLANCO, R., DOKOUPILOVÁ, E., VAN DE SANDE, M., HALL, A. WIKSTEN, B. O. PORTER, H. O. RICHARDS, S. HAEMMERLE a J. BRAUNS. Secukinumab significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 16-week results from the phase-iii PREVENT STUDY. 2020.

GENOVESE, M. C., LERTRATANAKUL, A. , ANDERSON, J., PAPP, K., TILLETT, W., VAN DEN BOSCH, F.,  TSUJI, S., DOKOUPILOVÁ, E., KEISERMAN, M., WANG, X.,  ZHONG, S., ZUEGER, P., PANGAN, A., MEASE, P. J. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2). 2020. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2020-eular.1229.

GRATACOS-MASMITJA, J., TURKIEWICZ, A., DOKOUPILOVÁ, E., GELLETT, A. M., SPRABERY, T., GENEUS, V. J.,  CONSTANTIN, A. Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to tnf inhibitors: three year results from a phase 3 study (SPIRIT-P2). 2020. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2020-eular.1482.

MEASE, P.J., LERTRATANAKUL, A., PAPP, K., VAN DEN BOSCH, F., TSUJI, S., DOKOUPILOVÁ, E., KEISERMAN, M., BU, X.,  CHEN, L.,  MCCASKILL, R.,  ZUEGER, P.,  MCDEARMON-BLONDELL, E., PANGAN, A.  TILLETT, W. Upadacitinib in patients with psoriatic arthritis refractory to biologic disease-modifying antirheumatic drugs: 56-week data from the phase 3 SELECT-PSA 2 STUDY. 2021. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2021-eular.1066.

PODDUBNYY, D., DEODHAR, A., BARALIAKOS, X., BLANCO, R., DOKOUPILOVÁ, E., HALL, S. KIVITZ, A.,  VAN DE SANDE, M.G.H.,  STEFANSKA, A., PERTEL, P., RICHARDS H., BRAUN, J. Secukinumab 150 mg provides sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis: 2-year results from the PREVENT STUDY. 2021. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2021-eular.143.

DE VLAM, K., TAYLOR, P., MEASE, P. J., PELOSO, P., WETZEL, D., BRUN, N., WIENS, B., BRANDT-JUERGENS, J., DRESCHER, E., DOKOUPILOVÁ, E., ROWINSKA-OSUCH, A., MARTIN, N. A.-K., BEHRENS, F. Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial. 2022. ISSN 2326-5191.

BEHRENS, F., TAYLOR, P. C., WETZEL, D., BRUN, N. C., BRANDT-JUERGENS, J., DRESCHER, E., DOKOUPILOVÁ, E., ROWINSKA-OSUCH, A., MARTIN, N. A.-K., DE VLAM, K. IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY. 2022. ISSN 0003-4967. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2022-eular.536.

TAYLOR, P., BEHRENS, F., MEASE, P.J., WETZEL, D., PELOSO, P., BRUN, N., WIENS, B., BRANDTJUERGENS, J., DRESCHER, E., DOKOUPILOVÁ, E., ROWINSKA-OSUCH, A., MARTIN, N. A.-K., DE VLAM, K. Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis. 2022. ISSN 2326-5191.

BEHRENS, F., TAYLOR, P., MEASE, P. J., PELOSO, P., WETZEL, D. BRUN, N., WIENS, B.,  BRANDT-JUERGENS, J., DRESCHER, E., DOKOUPILOVÁ, E., ROWINSKA-OSUCH, A., MARTIN, N. A.-K.,  Kurt DE VLAM, K. Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial. 2022. ISSN 2326-5191.

GOTTLIEB, A., MUENSTERMAN, E., KIVITZ, A., DOKOUPILOVA, E., LERTRATANAKUL, A., HONG, T., CHEN, J., BARALIAKOs, X. Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9)

KIVITZ, A., MUENSTERMAN, E., KAVANAUGH, A., VAN DER HEIJDE, D., KLIMIUK, P., VALENZUELA, G., DOKOUPILOVA, E., POIRIER, G., SRIVASTAVA, B., DASEN, S., ZHANG, X., TRIVEDI, M., WENG, H., HONG, T., POTHULA, P., BARALIAKOS, X. Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

MEASE, P., TAYLOR, P., DE VLAM, K., PELOSO, P., LERTRATANAKUL, A., WETZEL, D., BRUN, N., WIENS, B., BRANDT-JUERGENS, J., DRESCHER, E., DOKOUPILOVA, E., ROWIŃSKA-OSUCH, A., ABDEL-KADER MARTIN, N., BEHRENS, F. Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

EASTELL, R., LANGDAHL, B., CHUNG, Y., PLEBANSKI, R., CZERWINSKI, E., DOKOUPILOVA, E., SUPRONIK, J., ROSA, J., ROWIŃSKA-OSUCH, A., BAEK, K., URBONIENE, A., AHN, S., RHO, Y., BAN, J. A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

DEODHAR, A., SUPRONIK, J., KIVITZ, A., VALENZUELA, G., KAPUR, K., ROHRER, S., DOKOUPILOVA, E., RICHARDS, H., PAVELKA, K. Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

TAYLOR, P., DE VLAM, K., MEASE, P., PELOSO, P., WETZEL, D., LERTRATANAKUL, A., BRUN, N., WIENS, B., BRANDT-JUERGENS, J., DRESCHER, E., DOKOUPILOVA, E., ROWIŃSKA-OSUCH, A., ABDEL-KADER, MARTIN N., BEHRENS, F. Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).

GOTTLIEB, A., MUENSTERMAN, E., KIVITZ, A., DOKOUPILOVA, E., LERTRATANAKUL, A., HONG, T., CHEN, J., BARALIAKOS, X. Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9)

DEODHAR, A., DOKOUPILOVA, E., VIZCAYA, C., SUTARIYA, R., BAO, W., KAPUR, K., ROHRER, S., KIVITZ, A. Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9).

KIVITZ, A., MUENSTERMAN, E.T., KAVANAUGH, A., et al. OP0138 Efficacy And Safety Outcomes Of Tak-279, A Selective Oral Tyrosine Kinase 2 (Tyk2) Inhibitor, From A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial In Patients With Active Psoriatic Arthritis. Annals of the Rheumatic Diseases;2024;83:149-151.

EASTELL, R., LANGDAHL, B., CHUNG, Y.S., et al POS0085 A Randomized, Double-Blind, Phase Iii Study To Compare Sb16 (Proposed Denosumab Biosimilar) To Reference Denosumab In Patients With Postmenopausal Osteoporosis: 18-Month Results. Annals of the Rheumatic Diseases.2024;83: